A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dialysis patients with CKD stage IIIB to Vrandomized to Patiromer or placebo
This study is investigating a new medication called Patiromer, or Veltassa, to help people with moderate to severe kidney disease manage their potassium levels. These patients often need to take essential blood pressure medicines called RAAS inhibitors, but sometimes these drugs can cause potassium levels to go too high. When potassium gets too high, doctors may have to lower the dose of these important blood pressure medications or stop them altogether. This study aims to find out if Patiromer can help patients keep their potassium levels in a healthy range, so they can continue taking their full dose of RAAS inhibitor medicine. Researchers will compare Patiromer to a dummy pill (placebo) to see if it makes a difference.
At a glance
What is this study about?
When you have kidney disease, especially moderate to severe stages (known as CKD stages IIIB to V), your kidneys might not be able to get rid of potassium from your body as well as they should. This can lead to a condition called hyperkalemia, which means you have too much potassium in your blood. High potassium can be serious and affect your heart.
Many people with kidney disease also take important blood pressure medications called RAAS inhibitors. These medicines are very good for protecting your heart and kidneys. However, a side effect of RAAS inhibitors can be that they sometimes cause potassium levels to rise. If your potassium gets too high, your doctor might have to reduce the dose of these helpful medications or even stop them, which isn't ideal for your health.
This study, called a Phase III trial, is looking at a medicine called Patiromer (also known as Veltassa). Patiromer is designed to help lower potassium levels. The main goal is to see if Patiromer can help patients with kidney disease continue taking their RAAS inhibitor medications without their potassium levels getting too high. Researchers will compare Patiromer to a placebo (a dummy pill) to understand if it's effective in preventing patients from having to change or stop their RAAS inhibitor treatment due to high potassium.
Key takeaways
- The study aims to help people with kidney disease manage high potassium.
- It tests a new medicine called Patiromer (Veltassa) against a dummy pill (placebo).
- The goal is to help patients continue taking important blood pressure medicines.
- Participation involves regular clinic visits, blood tests, and taking the study medicine.
- It's a 'Phase III' clinical trial, assessing safety and effectiveness for wider use.
Who may be eligible?
This study is looking for adult men and women, aged 18 and older, who have moderate to severe kidney disease (specifically CKD stages IIIB to V). People must also have had issues with high potassium levels in their blood while taking blood pressure medicines called RAAS inhibitors.
To be considered, your potassium levels must have been too high (5.5 mEq/L or more) on two separate occasions, a week apart, despite your doctor's best efforts. You also can't be on dialysis.
If you meet these general criteria and your doctor thinks it's a good fit, you might be able to take part in this study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have moderate to severe kidney disease (CKD Stages IIIB to V)?
- Have you experienced high potassium levels (hyperkalemia) despite treatment?
- Are you currently taking or have you previously taken RAAS inhibitor medications?
- Are you not currently on dialysis?
What does participation involve?
If you join this study, you would be randomly assigned to receive either the study drug, Patiromer, or a placebo (a dummy pill). Neither you nor your study doctor would know which one you are taking. You will take the study drug or placebo by mouth.
Over the course of the study, you would have several visits to the clinic for check-ups. These visits will involve blood tests to measure your potassium levels and other important markers of kidney health. You may also have urine tests. Researchers will also look at your general health, blood pressure, and how you're feeling. The study will track how many people need to change or stop their blood pressure medication because of high potassium. The total duration of your participation in the study would depend on the study design, which isn't fully detailed here, but your study team would explain the schedule of visits and treatments in full.
Potential risks and benefits
Locations (1)
- —UnverifiedItaly
Common questions
What is hyperkalemia?
Hyperkalemia means you have too much potassium in your blood, which can be dangerous, especially for your heart.
What are RAAS inhibitors?
These are important blood pressure medications that protect your heart and kidneys, but they can sometimes raise potassium levels.
What is a placebo?
A placebo is a 'dummy' pill that looks just like the real medicine but contains no active drug. It helps researchers compare the real drug's effects.
What is CKD Stage IIIB to V?
This refers to moderate to severe stages of chronic kidney disease, where your kidneys are not working as well as they should.
Will I know if I'm getting the real medicine or the placebo?
No, this is a 'double-blind' study, meaning neither you nor your study doctor will know which treatment you are receiving until the study is over.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.